0001562180-15-000533.txt : 20150630 0001562180-15-000533.hdr.sgml : 20150630 20150630164847 ACCESSION NUMBER: 0001562180-15-000533 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150626 FILED AS OF DATE: 20150630 DATE AS OF CHANGE: 20150630 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tokai Pharmaceuticals Inc CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 255 STATE STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 617-225-4348 MAIL ADDRESS: STREET 1: 255 STATE STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Morrison Jodie Pope CENTRAL INDEX KEY: 0001618247 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 15961876 MAIL ADDRESS: STREET 1: C/O TOKAI PHARMACEUTICALS, INC. STREET 2: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2015-06-26 false 0001404281 Tokai Pharmaceuticals Inc TKAI 0001618247 Morrison Jodie Pope C/O TOKAI PHARMACEUTICALS, INC. 255 STATE STREET, 6TH FLOOR BOSTON MA 02109 true true false false President and CEO Common Stock 2015-06-26 4 M false 8000.00 1.58 A 17551.00 D Common Stock 2015-06-26 4 S false 8000.00 13.83 D 9551.00 D Common Stock 2015-06-29 4 M false 8000.00 1.58 A 17551.00 D Common Stock 2015-06-29 4 S false 8000.00 13.70 D 9551.00 D Stock Option (right to buy) 1.58 2015-06-26 4 M false 8000.00 0.00 D 2023-06-26 Common Stock 8000.00 333300.00 D Stock Option (right to buy) 1.58 2015-06-29 4 M false 8000.00 0.00 D 2023-06-26 Common Stock 8000.00 325300.00 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $14.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $13.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on June 26, 2013. With respect to 258,825 shares underlying the option, 2.0833% of those shares vested on July 1, 2013 and an additional 2.0833% of those shares vest on the first day of each month thereafter through June 1, 2017. With respect to 82,475 shares underlying the option, 8.333% of those shares vested on October 24, 2013 and an additional 2.0833% of those shares vest on the first day of each month thereafter through June 1, 2017. Upon the closing of the Issuers initial public offering in September 2014, the vesting for this option accelerated by 12 months. /s/ Cindy Driscoll, Attorney-in-Fact 2015-06-30